Private Cambridge, Massachusetts biotechnology company developing medicines that target protein-arginine deiminase (PAD) enzymes, with the goal of treating destructive autoimmune diseases
Private Cambridge, Massachusetts biotechnology company developing medicines that target protein-arginine deiminase (PAD) enzymes, with the goal of treating destructive autoimmune diseases. Its research focused on the role of protein citrullination in autoantigen generation, inflammation, and immune complex formation. Bristol Myers Squibb acquired the company in 2016.